In vivo T cell depletion in rheumatoid arthritis is associated with increased in vitro IgM-rheumatoid factor synthesis

Nancy Olsen, Grace P. Teal, Vibeke Strand

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

T cell depletion has been demonstrated to have therapeutic potential in patients with rheumatoid arthritis and several agents which deplete or inactivate T cells are currently being evaluated in clinical trials. We treated six patients with active rheumatoid arthritis with one such agent, the murine IgG1 anti-CD5 immunoconjugate CD5 Plus, as part of a multicenter trial. Measurement of in vitro synthesis of IgM and IgM-rheumatoid factor by peripheral blood mononuclear cells obtained from patients before, during, and after treatment, was performed using enzyme-linked immunoassays. Subsets of T and B lymphocytes were measured by flow cytometry. Significant T cell depletion was observed on Days 2 and 5 during the treatment period and was associated with increased in vitro rheumatoid factor (RF) production on Days 5 and 8 in 4 of the 5 patients with significant pretreatment levels of RF synthesis. No apparent relationship to serum RF levels or clinical responses was noted. These results implicate a role for T cells in the control of IgM-RF production in patients with rheumatoid arthritis.

Original languageEnglish (US)
Pages (from-to)124-129
Number of pages6
JournalClinical Immunology and Immunopathology
Volume67
Issue number2
DOIs
StatePublished - Jan 1 1993

Fingerprint

Rheumatoid Factor
Immunoglobulin M
Rheumatoid Arthritis
T-Lymphocytes
Immunoconjugates
B-Lymphocyte Subsets
T-Lymphocyte Subsets
Immunoenzyme Techniques
Multicenter Studies
Blood Cells
Flow Cytometry
Therapeutics
Immunoglobulin G
In Vitro Techniques
Clinical Trials
Serum

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Pathology and Forensic Medicine
  • Immunology

Cite this

@article{9c90c203e018475eb5bd70f040858457,
title = "In vivo T cell depletion in rheumatoid arthritis is associated with increased in vitro IgM-rheumatoid factor synthesis",
abstract = "T cell depletion has been demonstrated to have therapeutic potential in patients with rheumatoid arthritis and several agents which deplete or inactivate T cells are currently being evaluated in clinical trials. We treated six patients with active rheumatoid arthritis with one such agent, the murine IgG1 anti-CD5 immunoconjugate CD5 Plus, as part of a multicenter trial. Measurement of in vitro synthesis of IgM and IgM-rheumatoid factor by peripheral blood mononuclear cells obtained from patients before, during, and after treatment, was performed using enzyme-linked immunoassays. Subsets of T and B lymphocytes were measured by flow cytometry. Significant T cell depletion was observed on Days 2 and 5 during the treatment period and was associated with increased in vitro rheumatoid factor (RF) production on Days 5 and 8 in 4 of the 5 patients with significant pretreatment levels of RF synthesis. No apparent relationship to serum RF levels or clinical responses was noted. These results implicate a role for T cells in the control of IgM-RF production in patients with rheumatoid arthritis.",
author = "Nancy Olsen and Teal, {Grace P.} and Vibeke Strand",
year = "1993",
month = "1",
day = "1",
doi = "10.1006/clin.1993.1054",
language = "English (US)",
volume = "67",
pages = "124--129",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "2",

}

In vivo T cell depletion in rheumatoid arthritis is associated with increased in vitro IgM-rheumatoid factor synthesis. / Olsen, Nancy; Teal, Grace P.; Strand, Vibeke.

In: Clinical Immunology and Immunopathology, Vol. 67, No. 2, 01.01.1993, p. 124-129.

Research output: Contribution to journalArticle

TY - JOUR

T1 - In vivo T cell depletion in rheumatoid arthritis is associated with increased in vitro IgM-rheumatoid factor synthesis

AU - Olsen, Nancy

AU - Teal, Grace P.

AU - Strand, Vibeke

PY - 1993/1/1

Y1 - 1993/1/1

N2 - T cell depletion has been demonstrated to have therapeutic potential in patients with rheumatoid arthritis and several agents which deplete or inactivate T cells are currently being evaluated in clinical trials. We treated six patients with active rheumatoid arthritis with one such agent, the murine IgG1 anti-CD5 immunoconjugate CD5 Plus, as part of a multicenter trial. Measurement of in vitro synthesis of IgM and IgM-rheumatoid factor by peripheral blood mononuclear cells obtained from patients before, during, and after treatment, was performed using enzyme-linked immunoassays. Subsets of T and B lymphocytes were measured by flow cytometry. Significant T cell depletion was observed on Days 2 and 5 during the treatment period and was associated with increased in vitro rheumatoid factor (RF) production on Days 5 and 8 in 4 of the 5 patients with significant pretreatment levels of RF synthesis. No apparent relationship to serum RF levels or clinical responses was noted. These results implicate a role for T cells in the control of IgM-RF production in patients with rheumatoid arthritis.

AB - T cell depletion has been demonstrated to have therapeutic potential in patients with rheumatoid arthritis and several agents which deplete or inactivate T cells are currently being evaluated in clinical trials. We treated six patients with active rheumatoid arthritis with one such agent, the murine IgG1 anti-CD5 immunoconjugate CD5 Plus, as part of a multicenter trial. Measurement of in vitro synthesis of IgM and IgM-rheumatoid factor by peripheral blood mononuclear cells obtained from patients before, during, and after treatment, was performed using enzyme-linked immunoassays. Subsets of T and B lymphocytes were measured by flow cytometry. Significant T cell depletion was observed on Days 2 and 5 during the treatment period and was associated with increased in vitro rheumatoid factor (RF) production on Days 5 and 8 in 4 of the 5 patients with significant pretreatment levels of RF synthesis. No apparent relationship to serum RF levels or clinical responses was noted. These results implicate a role for T cells in the control of IgM-RF production in patients with rheumatoid arthritis.

UR - http://www.scopus.com/inward/record.url?scp=0027262440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027262440&partnerID=8YFLogxK

U2 - 10.1006/clin.1993.1054

DO - 10.1006/clin.1993.1054

M3 - Article

C2 - 7686090

AN - SCOPUS:0027262440

VL - 67

SP - 124

EP - 129

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 2

ER -